Southwest Oncology Group

Two decades of experience in non-small cell lung cancer

Andrew T. Turrisi, John Crowley, Kathy Albain, Laurie Gaspar, David R Gandara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume32
Issue numberSUPPL. 3
DOIs
StatePublished - Apr 2005

Fingerprint

Etoposide
Non-Small Cell Lung Carcinoma
Cisplatin
docetaxel
Radiotherapy
Esophagitis
Patient Selection
Thorax
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Southwest Oncology Group : Two decades of experience in non-small cell lung cancer. / Turrisi, Andrew T.; Crowley, John; Albain, Kathy; Gaspar, Laurie; Gandara, David R.

In: Seminars in Oncology, Vol. 32, No. SUPPL. 3, 04.2005.

Research output: Contribution to journalArticle

Turrisi, Andrew T. ; Crowley, John ; Albain, Kathy ; Gaspar, Laurie ; Gandara, David R. / Southwest Oncology Group : Two decades of experience in non-small cell lung cancer. In: Seminars in Oncology. 2005 ; Vol. 32, No. SUPPL. 3.
@article{e79e3a75503142418bb80ac509ba40b2,
title = "Southwest Oncology Group: Two decades of experience in non-small cell lung cancer",
abstract = "Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.",
author = "Turrisi, {Andrew T.} and John Crowley and Kathy Albain and Laurie Gaspar and Gandara, {David R}",
year = "2005",
month = "4",
doi = "10.1053/j.seminoncol.2005.03.022",
language = "English (US)",
volume = "32",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Southwest Oncology Group

T2 - Two decades of experience in non-small cell lung cancer

AU - Turrisi, Andrew T.

AU - Crowley, John

AU - Albain, Kathy

AU - Gaspar, Laurie

AU - Gandara, David R

PY - 2005/4

Y1 - 2005/4

N2 - Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.

AB - Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.

UR - http://www.scopus.com/inward/record.url?scp=18144410574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144410574&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2005.03.022

DO - 10.1053/j.seminoncol.2005.03.022

M3 - Article

VL - 32

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 3

ER -